



WILLIAMS, MORGAN & AMERSON, P.C.

10333 RICHMOND, STE. 1100, HOUSTON, TEXAS 77042

(713) 934-7000 FAX: (713) 934-7011

Danny L. Williams
Terry D. Morgan
J. Mike Amerson
Kenneth D. Goodman
Jeffrey A. Pyle
Jaison C. John
Ruben S. Bains
Scott F. Diring†

Shelley P.M. Fussey, Ph.D.*
Mark D. Moore, Ph.D.*
Raymund F. Eich, Ph.D.*
Daren C. Davis*
Stephanie A. Wardwell, Ph.D.*
Mark W. Sincell, Ph.D.*


*Patent Agent

†Licensed in Wisconsin,
not licensed in Texas

WRITER'S DIRECT DIAL:
713.934.4079

January 20, 2004

FILE: 3999.002587

CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
January 20, 2004	
Date	Shelley P.M. Fussey

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RE: *U.S. Patent Application Serial No. 10/738,404; Entitled: "Ant-VEGF Antibody Prodrug Methods (As Amended)"; Inventors: Thorpe and Brekken; Client Reference: UTSD:1412--8*

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, PTO-Form 1449 and copy of Reference A59.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Director is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/3999.002587

WILLIAMS, MORGAN & AMERSON, P.C.

Commissioner for Patents

January 20, 2004

Page 2

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Williams, Morgan & Amerson, P.C.

Customer No. 23720



Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458

Agent for Applicants

Encls.



CERTIFICATE OF MAILING
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

January 20, 2004

Date


Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Philip E. Thorpe and Rolf A. Brekken

Serial No.: 10/738,404

Filing Date: December 17, 2003

For: ANTI-VEGF ANTIBODY PRODRUG
METHODS (As Amended)

Group Art Unit: 1642

Examiner: Yaen, C.

Atty. Dkt. No.: 3999.002587

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that the present Supplemental Information Disclosure Statement be entered and the document listed on the enclosed Form PTO-1449 be considered by the Examiner and made of record in the present case. A copy of the listed document required by 37 C.F.R. § 1.98(a)(2) is enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees should be required. Even if an Official Action had been issued in the last few days, no fees would be required in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), the listed U.S. patent was not cited in a communication from a foreign patent office in a counterpart foreign application. This patent issued on January 13, 2004, and could not have been submitted prior to that date. As the application from which the patent issued has been disclosed to the Office, the patent is believed to be cumulative over the co-pending application of record. The patent issued from a co-pending application that has the same effective filing date as the present case, and so cannot be considered as "prior".


No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/3999.002587.

Respectfully submitted,
Williams, Morgan & Amerson, P.C.
Customer No. 23720



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

10333 Richmond, Suite 1100
Houston, Texas, 77042
(713) 934-4079
Date: January 20, 2004



Form PTO-1449 (modified)

Atty. Docket No.
3999.002587Serial No.
10/738,404

List of Patents and Publications for Applicant's

Applicant
Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
December 17, 2003

Group:

U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page*Other Art
See Page

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A59	6,676,941	Jan. 13, 2004	Thorpe <i>et al.</i>	424	178.1	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.